alexa Huanyu Dou | Texas tech University Health Sciences Cent
ISSN: 2157-7439

Journal of Nanomedicine & Nanotechnology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
 
 

Huanyu Dou

Huanyu Dou Huanyu Dou
Assistant Professor
Department of Biomedical Sciences
Texas tech University Health Sciences Center El Paso
USA
 
Biography

I was trained in neuroscience, neuroimmunology, immunology and nanomedicine and have combined these disciplines to lay a foundation for experimental studies into neuroimmunopharmacology, nanobiology and targeted brain delivery. The significance of my research lies in macrophage-targeted therapy for anti-viral and anti-cancer treatment. I developed RVG-nanocomplexes, as cell-based targeting for brain tumor targeting delivery to treat glioma. Importantly, tumor-associated macrophages and microglia (TAMs) have an extraordinary ability to home in on diseased brain sites as the targets, which provide an ideal therapeutic strategy by targeted delivery RVG-nanocomplexes to brain tumor. My current research is focused on the brain specific targeted delivery and cell-based therapies for brain tumor. My laboratory is applying basic biological techniques (in vitro, ex vivo, and in vivo) and nanotechnology to study newly emerging principles of cytokine and immune cells manipulating neuropathogenesis and ligand-nanoparticle conjungations for cell delivery platforms, especially for treatment of glioma. The proposed researches use RVG-nanocomplexe for glioma chemotherapy to better understanding on how the physicochemical properties to RVG-nanocomplexes can be optimized to maximize the dual benefits of a delivery vehicle across BBB and a specific glioma targeting tools. At present, I am studying the roles of conjugating RVG to core-shell structure of nanocomplexes for BBB-penetrating and gliomaassociated macrophages/microglia specific targeting will allow new chemotherapeutic strategy to be developed, therefore providing RVG-nanocomplexes brain tumor targeting delivery for anti-glioma chemotherapy. Based on macrophage affinity nanocomplexes as toxic therapeutics vehicle and RVG-AChR specific binding for brain targeting across BBB, optimizing RVG-nanocomplex and utilizing particle size will achieve for the specific brain tumor targeting and elimination neuronal cell uptake. To study and complete the proposed researches will have better view and direction on how to bring our innovative delivery platform and technology to clinic application in order to achieve our long-term goal of effectively treating glioma patients.

Research Interest

Medicine, Neuroanatomy, Neurosciences, Neurovirology, nanomedicine

Certificate
Certificate

Global Speakers in the subject

Global Experts in the subject

Publications

Size Effects of Nanocomplex on Tumor Associated Macrophages Targeted Delivery for Glioma
Lei Zou, Alejandro Macias sustaita, Tima Thomas, Lihn Do, Juan Rodriguez and Huanyu Dou*
Research Article: J Nanomed Nanotechnol 2015, 6:339
DOI: 10.4172/2157-7439.1000339
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords